The RA enrolled cohort was stratified according to the drug treatment: 5 patients were under TNF-α inhibitors, 8 were under IL-6 inhibitors, 11 were under CTLA-4-Ig, and 11 were under DMARDs only. Here, CTLA4 is linked to rheumatoid arthritis.